English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18054/20253 (89%)
Visitors : 24276032      Online Users : 408
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34704


    標題: High Expression of Folate Receptor Alpha (FOLR1) is Associated With Aggressive Tumor Behavior, Poor Response to Chemoradiotherapy, and Worse Survival in Rectal Cancer
    作者: Chen, Chih-I
    Li, Wan-Shan
    Chen, Hsin-Pao
    Liu, Kuang-Wen
    Tsai, Chia-Jen
    Hung, Wei-Ju
    Yang, Ching-Chieh
    貢獻者: E-Da Hospital
    I Shou University
    National Sun Yat Sen University
    Chi Mei Hospital
    Chung Hua University
    Department of Pharmacy, Chia Nan University of Pharmacy & Science
    關鍵字: preoperative chemoradiotherapy
    mirvetuximab soravtansine
    epithelial ovarian
    binding-protein
    chemotherapy
    carcinoma
    carcinogenesis
    antibody
    target
    日期: 2022
    上傳時間: 2023-12-11 14:06:07 (UTC+8)
    出版者: SAGE PUBLICATIONS INC
    摘要: Objectives: Recently, molecular medicine targeting Folate Receptor Alpha (FOLR1), which mediates intracellular folate uptake and tumor cell proliferation, has been identified in several malignancies. However, the association between FOLR1 expression and rectal cancer remains unclear. Methods: Immunostaining of FOLR1 was performed on biopsy specimens from 172 rectal cancer patients undergoing preoperative chemoradiotherapy (CRT). FOLR1 expression was measured and divided into low (0+-2+) or high (3+-4+) level. Correlations between FOLR1 status and clinicopathologic features, tumor regression grade, disease-specific survival (DSS), local recurrence-free survival, and metastasis-free survival (MeFS) were analyzed, retrospectively. Results: High FOLR1 expression was significantly associated with advanced post-treatment tumor and nodal status (T3-4; N1-2, P = .001), vascular invasion (P = .042), perineural invasion (P = .012), and poor regression change after CRT (P = .001). In uni- and multi-variable survival analysis, FOLR1 overexpression remained a significant predictor of lower DSS (hazard ratio [HR], 2.328; 95% confidence interval [CI], 1.014-5.344; P = .046) and MeFS (HR, 2.177; 95% CI, 1.000-1.1286; P = .050). Conclusion: These results indicate that high FOLR1 status is associated with aggressive tumor behavior, poor response to CRT, and worse survival. Therefore, FOLR1 expression at initial biopsy may be useful in predicting outcomes and also be a target for the exploration of FOLR1-based therapeutic agents.
    關聯: TECHNOLOGY IN CANCER RESEARCH & TREATMENT, v.21, January-December 2022
    Appears in Collections:[藥學系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML87View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback